US Stock MarketDetailed Quotes

CRSP CRISPR Therapeutics

Watchlist
  • 56.210
  • -4.270-7.06%
Close Jul 18 16:00 ET
  • 56.900
  • +0.690+1.23%
Post 19:31 ET
4.77BMarket Cap-20818P/E (TTM)

CRISPR Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
(Q2)Jun 30, 2022
Total revenue
0
84,762.39%370M
3,333,233.33%200M
0
44,203.80%70M
56,079.78%100M
-99.95%436K
-99.95%6K
-71.43%94K
-99.98%158K
Operating revenue
--0
84,762.39%370M
3,333,233.33%200M
--0
44,203.80%70M
56,079.78%100M
-99.95%436K
-99.95%6K
-71.43%94K
-99.98%158K
Cost of revenue
11.31%46.97M
18.14%130.25M
193.13%20M
-39.73%23.42M
31.58%44.64M
37.68%42.19M
8.97%110.25M
-78.56%6.82M
72.98%38.86M
25.89%33.92M
Gross profit
-181.24%-46.97M
318.32%239.75M
2,740.46%180M
39.58%-23.42M
175.12%25.36M
289.73%57.81M
-113.53%-109.81M
65.00%-6.82M
-75.13%-38.77M
-103.87%-33.76M
Operating expense
-23.45%93.62M
-17.94%462.29M
-11.47%110.42M
-24.11%108.99M
-19.34%120.59M
-15.95%122.3M
28.51%563.35M
-1.19%124.72M
34.59%143.62M
35.12%149.5M
Selling and administrative expenses
-19.71%17.95M
-25.67%76.16M
-22.16%16.48M
-32.26%18.29M
-27.56%19.03M
-20.20%22.36M
2.78%102.46M
-10.60%21.17M
13.89%27M
-8.79%26.27M
-General and administrative expense
-19.71%17.95M
-25.67%76.16M
-22.16%16.48M
-32.26%18.29M
-27.56%19.03M
-20.20%22.36M
2.78%102.46M
-10.60%21.17M
13.89%27M
-8.79%26.27M
Research and development costs
-23.78%76.17M
-16.10%387.33M
-8.12%95.14M
-22.23%90.7M
-17.58%101.56M
-15.48%99.94M
35.55%461.65M
0.45%103.56M
39.67%116.62M
49.67%123.22M
Other operating expenses
---504K
-58.27%-1.21M
----
----
----
----
59.51%-762K
--0
----
----
Operating profit
-118.01%-140.59M
66.94%-222.54M
152.90%69.58M
27.40%-132.41M
48.04%-95.22M
63.35%-64.49M
-280.22%-673.16M
9.72%-131.54M
-41.55%-182.39M
-124.03%-183.26M
Net non-operating interest income expense
Other net income (expense)
94.00%24.72M
216.91%71.82M
74.04%20M
184.57%20.67M
419.36%18.41M
3,410.19%12.74M
277.49%22.66M
422.99%11.49M
559.76%7.26M
372.53%3.54M
Other non- operating income (expenses)
94.00%24.72M
216.91%71.82M
74.04%20M
184.57%20.67M
419.36%18.41M
3,410.19%12.74M
277.49%22.66M
422.99%11.49M
559.76%7.26M
372.53%3.54M
Income before tax
-123.92%-115.87M
76.83%-150.72M
174.62%89.58M
36.19%-111.74M
57.26%-76.82M
70.53%-51.75M
-271.40%-650.5M
16.34%-120.05M
-37.09%-175.12M
-123.54%-179.72M
Income tax
-45.15%724K
988.62%2.89M
102.46%233K
171.65%412K
-84.91%923K
-63.41%1.32M
-117.38%-325K
-320.59%-9.48M
3.36%-575K
47.67%6.12M
Net income
-119.71%-116.59M
76.37%-153.61M
180.80%89.35M
35.75%-112.15M
58.17%-77.74M
70.39%-53.07M
-272.16%-650.18M
21.72%-110.58M
-37.27%-174.55M
-124.48%-185.83M
Net income continuous Operations
-119.71%-116.59M
76.37%-153.61M
180.80%89.35M
35.75%-112.15M
58.17%-77.74M
70.39%-53.07M
-272.16%-650.18M
21.72%-110.58M
-37.27%-174.55M
-124.48%-185.83M
Minority interest income
Net income attributable to the parent company
-119.71%-116.59M
76.37%-153.61M
180.80%89.35M
35.75%-112.15M
58.17%-77.74M
70.39%-53.07M
-272.16%-650.18M
21.72%-110.58M
-37.27%-174.55M
-124.48%-185.83M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-119.71%-116.59M
76.37%-153.61M
180.80%89.35M
35.75%-112.15M
58.17%-77.74M
70.39%-53.07M
-272.16%-650.18M
21.72%-110.58M
-37.27%-174.55M
-124.48%-185.83M
Basic earnings per share
-113.43%-1.43
76.79%-1.94
180.14%1.13
37.05%-1.41
59.17%-0.98
71.12%-0.67
-268.21%-8.36
23.37%-1.41
-34.13%-2.24
-123.98%-2.4
Diluted earnings per share
-113.43%-1.43
76.79%-1.94
180.14%1.13
37.05%-1.41
59.17%-0.98
71.12%-0.67
-277.87%-8.36
23.37%-1.41
-34.13%-2.24
-125.42%-2.4
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
--
--
--
Unqualified Opinion
--
--
--
(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022(Q2)Jun 30, 2022
Total revenue 084,762.39%370M3,333,233.33%200M044,203.80%70M56,079.78%100M-99.95%436K-99.95%6K-71.43%94K-99.98%158K
Operating revenue --084,762.39%370M3,333,233.33%200M--044,203.80%70M56,079.78%100M-99.95%436K-99.95%6K-71.43%94K-99.98%158K
Cost of revenue 11.31%46.97M18.14%130.25M193.13%20M-39.73%23.42M31.58%44.64M37.68%42.19M8.97%110.25M-78.56%6.82M72.98%38.86M25.89%33.92M
Gross profit -181.24%-46.97M318.32%239.75M2,740.46%180M39.58%-23.42M175.12%25.36M289.73%57.81M-113.53%-109.81M65.00%-6.82M-75.13%-38.77M-103.87%-33.76M
Operating expense -23.45%93.62M-17.94%462.29M-11.47%110.42M-24.11%108.99M-19.34%120.59M-15.95%122.3M28.51%563.35M-1.19%124.72M34.59%143.62M35.12%149.5M
Selling and administrative expenses -19.71%17.95M-25.67%76.16M-22.16%16.48M-32.26%18.29M-27.56%19.03M-20.20%22.36M2.78%102.46M-10.60%21.17M13.89%27M-8.79%26.27M
-General and administrative expense -19.71%17.95M-25.67%76.16M-22.16%16.48M-32.26%18.29M-27.56%19.03M-20.20%22.36M2.78%102.46M-10.60%21.17M13.89%27M-8.79%26.27M
Research and development costs -23.78%76.17M-16.10%387.33M-8.12%95.14M-22.23%90.7M-17.58%101.56M-15.48%99.94M35.55%461.65M0.45%103.56M39.67%116.62M49.67%123.22M
Other operating expenses ---504K-58.27%-1.21M----------------59.51%-762K--0--------
Operating profit -118.01%-140.59M66.94%-222.54M152.90%69.58M27.40%-132.41M48.04%-95.22M63.35%-64.49M-280.22%-673.16M9.72%-131.54M-41.55%-182.39M-124.03%-183.26M
Net non-operating interest income expense
Other net income (expense) 94.00%24.72M216.91%71.82M74.04%20M184.57%20.67M419.36%18.41M3,410.19%12.74M277.49%22.66M422.99%11.49M559.76%7.26M372.53%3.54M
Other non- operating income (expenses) 94.00%24.72M216.91%71.82M74.04%20M184.57%20.67M419.36%18.41M3,410.19%12.74M277.49%22.66M422.99%11.49M559.76%7.26M372.53%3.54M
Income before tax -123.92%-115.87M76.83%-150.72M174.62%89.58M36.19%-111.74M57.26%-76.82M70.53%-51.75M-271.40%-650.5M16.34%-120.05M-37.09%-175.12M-123.54%-179.72M
Income tax -45.15%724K988.62%2.89M102.46%233K171.65%412K-84.91%923K-63.41%1.32M-117.38%-325K-320.59%-9.48M3.36%-575K47.67%6.12M
Net income -119.71%-116.59M76.37%-153.61M180.80%89.35M35.75%-112.15M58.17%-77.74M70.39%-53.07M-272.16%-650.18M21.72%-110.58M-37.27%-174.55M-124.48%-185.83M
Net income continuous Operations -119.71%-116.59M76.37%-153.61M180.80%89.35M35.75%-112.15M58.17%-77.74M70.39%-53.07M-272.16%-650.18M21.72%-110.58M-37.27%-174.55M-124.48%-185.83M
Minority interest income
Net income attributable to the parent company -119.71%-116.59M76.37%-153.61M180.80%89.35M35.75%-112.15M58.17%-77.74M70.39%-53.07M-272.16%-650.18M21.72%-110.58M-37.27%-174.55M-124.48%-185.83M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -119.71%-116.59M76.37%-153.61M180.80%89.35M35.75%-112.15M58.17%-77.74M70.39%-53.07M-272.16%-650.18M21.72%-110.58M-37.27%-174.55M-124.48%-185.83M
Basic earnings per share -113.43%-1.4376.79%-1.94180.14%1.1337.05%-1.4159.17%-0.9871.12%-0.67-268.21%-8.3623.37%-1.41-34.13%-2.24-123.98%-2.4
Diluted earnings per share -113.43%-1.4376.79%-1.94180.14%1.1337.05%-1.4159.17%-0.9871.12%-0.67-277.87%-8.3623.37%-1.41-34.13%-2.24-125.42%-2.4
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------------Unqualified Opinion------

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg
Concept Gene Editing
Gene Editing
Intraday-0.76%
ARK Holdings
ARK Holdings
Intraday-0.79%